Live Demo:
This is a live DrugChatter demonstration using real AI-generated drug queries and analysis.
Want to see how your drug is represented by AI?
Contact DrugChatter
keytruda
Brand Visibility Tracking
How this brand shows up in AI chatbot answers — presence, position, sentiment, and how it stacks up against competitors.
–
Score / 100
Latest check
Weighted composite of presence, position, sentiment, and recommendation strength across tracked prompts.
Presence
–
Avg. position
–
Lower is betterSentiment
–
Recommendation mix — latest check
How the brand was framed across the latest tracked prompts.
Competitive landscape — latest check
Visibility vs. sentiment. Bubble size reflects rank position (bigger = higher-ranked).
Best known for — latest check
Head-to-head evidence exists in some situations
Both are PD-1 inhibitors.
Go-to agent for that indication/biomarker combination.
Core Claims — latest check
Keytruda is the brand name for pembrolizumab.
There is not an interchangeable generic 'pembrolizumab' in the usual small-molecule sense, because it’s a biologic monoclonal antibody.
Keytruda = pembrolizumab.
Indications overlap but are not identical.
Efficacy is often 'comparable' but not always equivalent.
Differentiators — latest check
Different antibodies (Keytruda is pembrolizumab; Opdivo is nivolumab).
Dosing schedules differ and indications differ by cancer type.
Combination regimens differ: Keytruda is commonly used in combinations; Opdivo is also used in combinations.
No universal generic; biosimilars may exist depending on location.
Efficacy is broadly similar but cancer-specific.
Competitor comparison — latest check
| Brand | Visibility | Sentiment | Position | Recommended |
|---|
30-day composite trends
Score
Overall composite score, per day.
Visibility vs. sentiment
Two lenses on the same conversations — how much the brand shows up, and how it's spoken about.
Average rank position
Where the brand lands among all brands mentioned, in reading order. Lower is better.
Recent checks
| Date | Score | Visibility | Position | Sentiment |
|---|---|---|---|---|
| Aug 12, 2026 | 58 | 66 | 1 | 53 |
| Aug 14, 2026 | 66 | 68 | 1 | 55 |
| Aug 15, 2026 | 62 | 62 | 1 | 52 |
| Aug 16, 2026 | 58 | 67 | 1 | 54 |
| Aug 17, 2026 | 59 | 68 | 1 | 53 |
| Aug 18, 2026 | 66 | 68 | 1 | 50 |
| Aug 19, 2026 | 62 | 68 | 1 | 57 |
| Aug 20, 2026 | 60 | 72 | 1 | 50 |
| Aug 21, 2026 | 51 | 63 | 1 | 58 |